A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Integrated Bone Formation Through In Vivo Endochondral Ossification Using Mesenchymal Stem Cells

2.1K views

⸱

DOI:

10.3791/65573

⸱

July 14th, 2023

 ,  ,  , 
1Department of Molecular Craniofacial Embryology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 2Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 3Department of Regenerative and Reconstructive Dental Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

In This Article

Summary

Bone therapy via endochondral ossification by implanting artificial cartilage tissue produced from mesenchymal stem cells has the potential to circumvent the drawbacks of conventional therapies. Hyaluronic acid hydrogels are effective in scaling up uniformly differentiated cartilage grafts as well as creating integrated bone with vascularization between fused grafts in vivo.

Abstract

Conventional bone regeneration therapy using mesenchymal stem cells (MSCs) is difficult to apply to bone defects larger than the critical size because it does not have a mechanism to induce angiogenesis. Implanting artificial cartilage tissue fabricated from MSCs induces angiogenesis and bone formation in vivo via endochondral ossification (ECO). Therefore, this ECO-mediated approach may be a promising bone regeneration therapy in the future. An important aspect of the clinical application of this ECO-mediated approach is establishing a protocol for preparing enough cartilage to be implanted to repair the bone defect. It is especially not practical to design a single mass of grafted cartilage of a size that conforms to the shape of the actual bone defect. Therefore, the cartilage to be transplanted must have the property of forming bone integrally when multiple pieces are implanted. Hydrogels may be an attractive tool for scaling up tissue-engineered grafts for endochondral ossification to meet clinical requirements. Although many naturally derived hydrogels support MSC cartilage formation in vitro and ECO in vivo, the optimal scaffold material to meet the needs of clinical applications has yet to be determined. Hyaluronic acid (HA) is a crucial component of the cartilage extracellular matrix and is a biodegradable and biocompatible polysaccharide. Here, we show that HA hydrogels have excellent properties to support in vitro differentiation of MSC-based cartilage tissue and promote endochondral bone formation in vivo.

Introduction

Autologous bone is still the gold standard for repairing bone defects due to trauma, congenital defects, and surgical resection. However, autogenous bone grafting has significant limitations, including donor pain, risk of infection, and limited bone volume that can be isolated from the patients1,2,3,4. Numerous biomaterials have been developed as bone substitutes, combining natural or synthetic polymers with mineralized materials such as calcium phosphate or hydroxyapatite5,6. Bone formation in these engineered materials is usually achieved using the mineralized material as a priming material to allow stem cells to differentiate directly into osteoblasts through the intramembrane ossification (IMO) process7. This process lacks the angiogenic step, resulting in insufficient in vivo vascularization of the graft after implantation8,9,10, and therefore, approaches using such a process may not be optimal for treating large bone defects11.

Strategies applied to recapitulate the endochondral ossification (ECO) process, an innate mechanism in skeletogenesis during development, have been shown to overcome significant problems associated with traditional IMO-based approaches. In ECO, chondrocytes in the cartilage template release vascular endothelial growth factor (VEGF), which promotes vascular infiltration and remodeling of the cartilage template into bone12. The ECO-mediated approach to osteogenesis via cartilage remodeling and angiogenesis, which is also activated during fracture repair, uses artificially created cartilage tissue derived from MSCs as a priming material. Chondrocytes can tolerate hypoxia in bone defects, induce angiogenesis, and convert a vascular-free cartilage graft into angiogenic tissue. Numerous studies have reported that MSC-based cartilage grafts generate bone in vivo by implementing such an ECO program13,14,15,16,17,18,19,20,21.

An essential requirement for the clinical application of this ECO-mediated approach is how to prepare the desired amount of cartilage graft in a clinical setting. Preparing clinical cartilage of a size that fits the actual bone defect is not practical. Therefore, graft cartilage must form bone integrally when multiple fragments are implanted22. Hydrogels may be an attractive tool for scaling up tissue-engineered grafts for endochondral ossification. Many naturally derived hydrogels support MSC cartilage formation in vitro and ECO in vivo23,24,25,26,27,28,29,30,31,32; however, the optimal support material to meet the clinical application requirements has remained undetermined. Hyaluronic acid (HA) is a biodegradable and biocompatible polysaccharide present in the extracellular matrix of cartilage33. HA interacts with MSCs via surface receptors such as CD44 to support chondrogenic differentiation25,26,28,30,31,32,34. In addition, HA scaffolds promote IMO-mediated osteogenic differentiation of human dental pulp stem cells35, and scaffolds combined with collagen promote ECO-mediated osteogenesis36,37.

Here, we present a method for preparing HA hydrogels using bone marrow-derived adult human MSCs and their use for hypertrophic chondrogenesis in vitro and subsequent endochondral ossification in vivo38. We compared the characteristics of HA with those of collagen, a material widely applied in bone tissue engineering with MSCs and a useful material for scaling up artificial grafts for endochondral ossification17. In an immunocompromised mouse model, HA and collagen constructs seeded with human MSCs were evaluated for in vivo ECO potential by subcutaneous implantation. The results show that HA hydrogels are excellent as a scaffold for MSCs to create artificial cartilage grafts that allow bone formation through ECO.

The protocol is divided into two steps. First, constructs of human MSCs seeded on hyaluronan hydrogel are prepared and differentiated into hypertrophic cartilage in vitro. Next, the differentiated constructs are implanted subcutaneously in a nude model to induce endochondral ossification in vivo (Figure 1).

Access restricted. Please log in or start a trial to view this content.

Protocol

This protocol uses 4-week-old male nude mice. House four mice in a cage under a 12 h light/dark cycle at 22−24 °C and 50%−70% relative humidity. All animal experiments were conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University (approval ID: A2019-204C, A2020-116A, and A2021-121A).

1. Preparation of buffers and reagents

  1. Prepare mesenchymal stem cell growth medium (MSC growth medium) by adding the supplement kit of MSC growth medium to MSC basal media and store it at 4 °C.
  2. Prepare Dulbecco's Modified Eagle Medium and Ham's F12 (DMEM/F-12) medium by adding 10% fetal bovine serum (FBS), 50 µg/mL gentamicin, 200 µM L-alanyl-L-glutamine, and 1 ng/mL basic fibroblastic growth factor to the medium and store it at 4 °C.
  3. Prepare chondrogenic medium by adding 1% ITS-G supplement, 0.12% bovine serum albumin, 50 µg/mL gentamicin, 0.35 mM L-proline, 100 nM dexamethasone, and 10 ng/mL TGF-β3 to DMEM just before use.
  4. Prepare hypertrophic medium by adding 10 mM β-glycerophosphate, 0.12% bovine serum albumin, 10 nM dexamethasone, 200 µM ascorbate-2-phosphate, 50 nM L-thyroxine, 50 µg/mL gentamycin, and 50 pg/mL IL-1β to DMEM just before use.
  5. Coat a 24-well culture dish with 200 µL of melted paraffin pre-heated at 60 °C. Allow to stand at room temperature until the paraffin is set.

2. Expansion of human MSCs

NOTE: Prior to starting the experiments, MSCs with a high potential for MSC chondrogenesis should be selected in micro mass culture as described in17.

  1. According to the manufacturer's instructions, culture primary human bone marrow-derived MSCs (passage 2) with MSC growth medium in a 10 cm dish at a density of 5 x 103 cells/cm2 at 37 °C in 5% CO2 and 95% humidified air incubator.
  2. Change the medium every 2-3 days. Once the cells reach 80%-90% confluency, aspirate the medium from the cell culture dish using a vacuum pump, wash with 5 mL of PBS, and then aspirate the solution with a vacuum pump.
  3. Add 1 mL of 0.05% trypsin/0.02% EDTA solution to the dish. Incubate the dish for 5-10 min at 37 °C.
  4. Add 1 mL of MSC growth medium to stop the enzymatic reaction. Transfer the cell suspension to a 50 mL tube.
  5. Combine the cell suspension from other dishes in the 50 mL tube and keep it on ice.
  6. Use the cell counter to count the cells by mixing 10 µL of the cell suspension with 10 µL of 0.4% trypan blue stain.
  7. Centrifuge the remaining cell suspension at 220 x g for 3 min at room temperature. Remove the supernatant and add cryopreservation solution at a concentration of 1.0 x 106 cells per mL.
  8. Dispense 1 mL of the cell suspension into each cryotube and store at -80 °C for 12 h before transferring to liquid nitrogen. The resulting frozen stocks (passage 3) are used for this protocol.
  9. For the experiments, seed the stocked MSCs in a 10 cm dish at a density of 5 x 103 cells/cm2. Culture cells until 80%-90% confluent (passage 4) in DMEM/F-12 medium.

3. Preparation of MSC-encapsulated hydrogels

  1. Trypsinize the cells and prepare cell suspension as described in steps 2.3 - 2.6.
  2. To make 10 constructs (2.5 x 105 cells per construct), aliquot the cell suspension containing 2.5 x 106 cells into a 1.5 mL microtube.
  3. Centrifuge the suspension at 220 x g for 3 min, remove the supernatant with a vacuum pump, and keep it on ice.
  4. Bring the thiol-modified hyaluronic acid (HA), thiol-reactive crosslinker, polyethylene glycol diacrylate, and degassed water bottles to room temperature.
  5. Under sterile conditions, add 1.0 mL of degassed water to the HA-containing bottle (see manufacturer's instructions) using a syringe with a needle.
  6. Vortex occasionally warming to 37 °C until the solution becomes clear, then place on ice. It takes less than 30 min for the solids to dissolve completely.
  7. Under sterile conditions, add 0.5 mL of degassed water to the crosslinker bottle using a syringe with a needle. Dissolve by inverting several times, then place on ice.
  8. Add 120 µL of the dissolved HA solution to the aliquoted cell pellet (2.5 x 106 cells). Resuspend the cell pellet by pipetting back and forth.
  9. Add 30 µL of the dissolved crosslinker solution to the tube containing the HA and cells (step 3.8) and combine by tapping the tube, and then spin down briefly. Combine the HA solution and the crosslinker solution in a 4:1 ratio.
  10. Drop 15 µL of the combined solution containing MSCs (2.5 x 105 cells) onto the paraffin-coated 24-well plate and allow it to solidify at 37 °C for 30 min (Figure 2). Due to high viscosity, prepare at least 10% extra amount of the cell/hydrogel mixture than needed.
    ​NOTE: The characteristics of the hydrogel have been described previously39.

4. In vitro differentiation conditions

  1. Add 0.5 mL of chondrogenic differentiation medium to a construct of MSC-seeded HA hydrogels. Change the medium every 2-3 days.
  2. After 3 weeks, switch to hypertrophic differentiation medium (0.5 mL per well) and culture the constructs for an additional 2 weeks.

5. In vivo implantation of MSCs

  1. After a total of 5 weeks of in vitro culture, implant the constructs subcutaneously into the back of nude mice as described previously38,40.
  2. Weigh mice and administer a combination anesthetic prepared with 0.75 mg/kg body weight (b.w.) medetomidine, 4.0 mg/kg b.w. midazolam, and 5.0 mg/kg b.w. butorphanol by intraperitoneal injection as described38.
  3. Confirm adequate anesthesia by immobility to surgical stimuli and monitor respiratory depth by slow, regular chest movements and proper oxygen supply by the color of the pink mucosa periodically during the operation. Use veterinary ointment on the eyes to prevent dryness during anesthesia.
  4. Place the mouse on a sterile surgical drape in a prone position, sterilize the incision site with 50 ppm hypochlorous acid water (pH 5.0; HAW), and place a perforated surgical drape over the mouse.
    ​NOTE: Sterilize all surgical materials in an autoclave, ethylene oxide gas, or HAW. The surgeons should wash their fingers and wear surgical gowns and gloves.
  5. Make two 5 mm long skin incisions 2 cm apart in the shoulder and hip areas along the center line of the spine by using scissors.
  6. Insert a spatula subcutaneously through the incision to create a subcutaneous pocket.
  7. Insert two to three constructs (~15 µL each, step 5.1) into each pocket with forceps. HA constructs implanted in the same pocket are prone to fusion very frequently. To prevent fusion, insert one HA construct in each pocket.
  8. Close the incisions with 4-0 braided silk sutures. Inject the mouse with an antagonist to anesthetics prepared with 0.75 mg/kg b.w. atipamezole as described38.
  9. While the mice recover from anesthesia, place the mice in sterile recovery cages containing sterile floor bedding without food and water bottles and continuously monitor body temperature, pulse, and respiration.
  10. Do not leave the mice unattended until it has regained sufficient consciousness to maintain sternal recumbency. After full recovery, return the animals to the breeding room with the other animals.
  11. Monitor the animals every couple of days during the healing period for any possible complications. Euthanize the mice by carbon dioxide inhalation with little suffering at 4- and 8-weeks post-implantation.
  12. Incise the skin at the grafted sites and remove the implanted constructs with forceps. Fix the constructs in 4% paraformaldehyde for 16 h and then subject them to analysis.

6. Statistical analysis

  1. Report quantitative data as mean ± standard deviation (SD). Perform statistical analysis using commercial software.
  2. Use the Student's t-test or one-way ANOVA followed by Tukey's multiple comparisons test to determine significant differences between groups. p<0.05 and p<0.01 indicate significant differences between two groups.

Access restricted. Please log in or start a trial to view this content.

Results

MSC-encapsulated HA hydrogels were cultured in chondrogenic medium supplemented with TGFβ3, an inducer of chondrogenesis41 (step 4.1). We compared the properties of HA with those of collagen, which has been shown to be effective in creating MSC-based artificial cartilage grafts for endochondral ossification, as described previously38. Undifferentiated MSCs were not included as negative controls in this study because it has been demonstrated that undifferentiated MSCs requir...

Access restricted. Please log in or start a trial to view this content.

Discussion

Using appropriate scaffold materials that promote the transition from hypertrophic cartilage to bone is a promising approach to scale up MSC-based engineered hypertrophic cartilage grafts and treat bone defects of clinically significant size. Here, we show that HA is an excellent scaffold material to support the differentiation of MSC-based hypertrophic cartilage tissue in vitro and to promote endochondral bone formation in vivo38. Furthermore, in vivo, HA constructs wer...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have declared that no competing interests exist.

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS) (grant nos. JP19K10259 and 22K10032 to MAI).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.25w/v% Trypsin-1mmol/L EDTA.4Na SolutionFUJIFILM Wako Pure Chemical 209-16941
AntisedanNippon Zenyaku Kogyo
ascorbate-2-phosphateNacalai Tesque13571-14
BambankerGC LymphotecCS-02-001
basic fibroblastic growth factorReprocellRCHEOT002 
bovine serum albuminFUJIFILM Wako Pure Chemical 012-238817.5 w/v%
Countess Automated Cell Counter with cell counting chamber slides and Trypan Blue stain 0.4%InvitrogenC10283
dexamethasoneMerckD8893
DomitorNippon Zenyaku Kogyo
DormicumAstellas Pharma
Dulbecco's Modified Eagle MediumMerckD6429high glucose
Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12 HamMerckD6421
Fetal bovine serumHycloneSH30396.03
Gentamicin sulfateFUJIFILM Wako Pure Chemical 1676045 10 mg/mL
Haccpper GeneratorTechnoMaxCH-400-5QB50 ppm hypochlorous acid water
Human Mesenchymal Stem CellsLonzaPT-2501
HyStem Cell Culture Scaffold KitMerckHYS020
IL-1ßPeproTechAF-200-01B
ITS-G supplementFUJIFILM Wako Pure Chemical 090-06741×100
L-Alanyl-L-GlutamineFUJIFILM Wako Pure Chemical 016-21841200mmol/L (×100)
L-prolineNacalai Tesque29001-42
L-ThyroxineMerckT1775
MSCGM Mesenchymal Stem Cell Growth Medium
BulletKit		LonzaPT-3001
paraffinFUJIFILM Wako Pure Chemical 165-13375
PBS / pH7.4 100mlMedicago09-2051-100
TGF-β3 ProteintechHZ-1090
VetorphaleMeiji Seika Kaisha
Visiocare OintmentSAVAVET/SAVA Healthcare
β-glycerophosphateFUJIFILM Wako Pure Chemical 048-34332

References

  1. Goldberg, V. M., Stevenson, S. Natural history of autografts and allografts. Clinical Orthopaedics and Related Research. (225), 7-16 (1987).
  2. Amini, A. R., Laurencin, C. T., Nukavarapu, S. P. Bone tissue engineering: recent advances and challenges. Critical Reviews in Biomedical Engineering. 40 (5), 363-408 (2012).
  3. Vining, N. C., Warme, W. J., Mosca, V. S. Comparison of structural bone autografts and allografts in pediatric foot surgery. Critical Reviews in Biomedical Engineering. 32 (7), 719-723 (2012).
  4. Roddy, E., DeBaun, M. R., Daoud-Gray, A., Yang, Y. P., Gardner, M. J. Treatment of critical-sized bone defects: clinical and tissue engineering perspectives. European Journal of Orthopaedic Surgery and Traumatology. 28 (3), 351-362 (2018).
  5. Rezwan, K., Chen, Q. Z., Blaker, J. J., Boccaccini, A. R. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 27 (18), 3413-3431 (2006).
  6. Swetha, M., et al. Biocomposites containing natural polymers and hydroxyapatite for bone tissue engineering. International Journal of Biological Macromolecules. 47 (1), 1-4 (2010).
  7. Meijer, G. J., de Bruijn, J. D., Koole, R., van Blitterswijk, C. A. Cell-based bone tissue engineering. PLOS Medicine. 4 (2), e9(2007).
  8. Tremblay, P. L., Hudon, V., Berthod, F., Germain, L., Auger, F. A. Inosculation of tissue-engineered capillaries with the host's vasculature in a reconstructed skin transplanted on mice. American Journal of Transplantation. 5 (5), 1002-1010 (2005).
  9. Ko, H. C., Milthorpe, B. K., McFarland, C. D. Engineering thick tissues--the vascularisation problem. European Cells and Materials. 14, 1-19 (2007).
  10. Santos, M. I., Reis, R. L. Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges. Macromolecular Bioscience. 10 (1), 12-27 (2010).
  11. Almubarak, S., et al. Tissue engineering strategies for promoting vascularized bone regeneration. Bone. 83, 197-209 (2016).
  12. Kronenberg, H. M. Developmental regulation of the growth plate. Nature. 423 (6937), 332-336 (2003).
  13. Farrell, E., et al. Chondrogenic priming of human bone marrow stromal cells: a better route to bone repair. Tissue Engineering Part C: Methods. 15 (2), 285-295 (2009).
  14. Scotti, C., et al. Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proceedings of the National Academy of Sciences of the United States of America. 107 (16), 7251-7256 (2010).
  15. Janicki, P., Kasten, P., Kleinschmidt, K., Luginbuehl, R., Richter, W. Chondrogenic pre-induction of human mesenchymal stem cells on beta-TCP: enhanced bone quality by endochondral heterotopic bone formation. Acta Biomaterialia. 6 (8), 3292-3301 (2010).
  16. Farrell, E., et al. In-vivo generation of bone via endochondral ossification by in-vitro chondrogenic priming of adult human and rat mesenchymal stem cells. BMC Musculoskeletal Disorders. 12, 31(2011).
  17. Scotti, C., et al. Engineering of a functional bone organ through endochondral ossification. Proceedings of the National Academy of Sciences of the United States of America. 110 (10), 3997-4002 (2013).
  18. Harada, N., et al. Bone regeneration in a massive rat femur defect through endochondral ossification achieved with chondrogenically differentiated MSCs in a degradable scaffold. Biomaterials. 35 (27), 7800-7810 (2014).
  19. van der Stok, J., et al. Chondrogenically differentiated mesenchymal stromal cell pellets stimulate endochondral bone regeneration in critical-sized bone defects. European Cells and Materials. 27, 137-148 (2014).
  20. Sheehy, E. J., Vinardell, T., Toner, M. E., Buckley, C. T., Kelly, D. J. Altering the architecture of tissue engineered hypertrophic cartilaginous grafts facilitates vascularisation and accelerates mineralisation. PLoS One. 9 (3), e90716(2014).
  21. Sheehy, E. J., Mesallati, T., Vinardell, T., Kelly, D. J. Engineering cartilage or endochondral bone: a comparison of different naturally derived hydrogels. Acta Biomaterialia. 13, 245-253 (2015).
  22. Bahney, C. S., et al. Stem cell-derived endochondral cartilage stimulates bone healing by tissue transformation. Journal of Bone and Mineral Research. 29 (5), 1269-1282 (2014).
  23. Mauck, R. L., Yuan, X., Tuan, R. S. Chondrogenic differentiation and functional maturation of bovine mesenchymal stem cells in long-term agarose culture. Osteoarthritis Cartilage. 14 (2), 179-189 (2006).
  24. Dickhut, A., Gottwald, E., Steck, E., Heisel, C., Richter, W. Chondrogenesis of mesenchymal stem cells in gel-like biomaterials in vitro and in vivo. Frontiers in Bioscience. 13, 4517-4528 (2008).
  25. Chung, C., Burdick, J. A. Influence of three-dimensional hyaluronic acid microenvironments on mesenchymal stem cell chondrogenesis. Tissue Engineering Part A. 15 (2), 243-254 (2009).
  26. Erickson, I. E., et al. Macromer density influences mesenchymal stem cell chondrogenesis and maturation in photocrosslinked hyaluronic acid hydrogels. Osteoarthritis Cartilage. 17 (12), 1639-1648 (2009).
  27. Sheehy, E. J., Buckley, C. T., Kelly, D. J. Chondrocytes and bone marrow-derived mesenchymal stem cells undergoing chondrogenesis in agarose hydrogels of solid and channelled architectures respond differentially to dynamic culture conditions. Journal of tissue engineering and regenerative medicine. 5 (9), 747-758 (2011).
  28. Erickson, I. E., et al. High mesenchymal stem cell seeding densities in hyaluronic acid hydrogels produce engineered cartilage with native tissue properties. Acta Biomaterialia. 8 (8), 3027-3034 (2012).
  29. Ma, K., Titan, A. L., Stafford, M., Zheng, C., Levenston, M. E. Variations in chondrogenesis of human bone marrow-derived mesenchymal stem cells in fibrin/alginate blended hydrogels. Acta Biomaterialia. 8 (10), 3754-3764 (2012).
  30. Levett, P. A., et al. A biomimetic extracellular matrix for cartilage tissue engineering centered on photocurable gelatin, hyaluronic acid and chondroitin sulfate. Acta Biomaterialia. 10 (1), 214-223 (2014).
  31. Reppel, L., et al. Chondrogenic induction of mesenchymal stromal/stem cells from Wharton's jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering. Stem Cell Research & Therapy. 6, 260(2015).
  32. Amann, E., Wolff, P., Breel, E., van Griensven, M., Balmayor, E. R. Hyaluronic acid facilitates chondrogenesis and matrix deposition of human adipose derived mesenchymal stem cells and human chondrocytes co-cultures. Acta Biomaterialia. 52, 130-144 (2017).
  33. Hemshekhar, M., et al. Emerging roles of hyaluronic acid bioscaffolds in tissue engineering and regenerative medicine. International Journal of Biological Macromolecules. 86, 917-928 (2016).
  34. Pfeifer, C. G., et al. Higher Ratios of Hyaluronic Acid Enhance Chondrogenic Differentiation of Human MSCs in a Hyaluronic Acid-Gelatin Composite Scaffold. Materials (Basel). 9 (5), (2016).
  35. La Noce, M., et al. Hyaluronan-Based Gel Promotes Human Dental Pulp Stem Cells Bone Differentiation by Activating YAP/TAZ Pathway. Cells. 10 (11), (2021).
  36. Thompson, E. M., Matsiko, A., Kelly, D. J., Gleeson, J. P., O'Brien, F. J. An Endochondral Ossification-Based Approach to Bone Repair: Chondrogenically Primed Mesenchymal Stem Cell-Laden Scaffolds Support Greater Repair of Critical-Sized Cranial Defects Than Osteogenically Stimulated Constructs In Vivo. Tissue Engineering Part A. 22 (5-6), 556-567 (2016).
  37. Wang, H., et al. Cell-mediated injectable blend hydrogel-BCP ceramic scaffold for in situ condylar osteochondral repair. Acta Biomaterialia. 123, 364-378 (2021).
  38. Yamazaki, S., et al. Hyaluronic acid hydrogels support to generate integrated bone formation through endochondral ossification in vivo using mesenchymal stem cells. PLoS One. 18 (2), e0281345(2023).
  39. Zarembinski, T., Skardal, A. Hydrogels - Smart Materials for Biomedical Applications. , (2019).
  40. Vinardell, T., Sheehy, E. J., Buckley, C. T., Kelly, D. J. A comparison of the functionality and in vivo phenotypic stability of cartilaginous tissues engineered from different stem cell sources. Tissue Engineering Part A. 18 (11-12), 1161-1170 (2012).
  41. Mueller, M. B., et al. Hypertrophy in mesenchymal stem cell chondrogenesis: effect of TGF-beta isoforms and chondrogenic conditioning. Cells Tissues Organs. 192 (3), 158-166 (2010).
  42. Lertkiatmongkol, P., Liao, D., Mei, H., Hu, Y., Newman, P. J. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Current Opinion in Hematology. 23 (3), 253-259 (2016).
  43. Kloxin, A. M., Kasko, A. M., Salinas, C. N., Anseth, K. S. Photodegradable hydrogels for dynamic tuning of physical and chemical properties. Science. 324 (5923), 59-63 (2009).
  44. Chan, C. K., et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature. 457 (7228), 490-494 (2009).
  45. Murdoch, A. D., et al. Chondrogenic differentiation of human bone marrow stem cells in transwell cultures: generation of scaffold-free cartilage. Stem Cells. 25 (11), 2786-2796 (2007).
  46. Tortelli, F., Tasso, R., Loiacono, F., Cancedda, R. The development of tissue-engineered bone of different origin through endochondral and intramembranous ossification following the implantation of mesenchymal stem cells and osteoblasts in a murine model. Biomaterials. 31 (2), 242-249 (2010).
  47. Knuth, C. A., Witte-Bouma, J., Ridwan, Y., Wolvius, E. B., Farrell, E. Mesenchymal stem cell-mediated endochondral ossification utilising micropellets and brief chondrogenic priming. European Cells and Materials. 34, 142-161 (2017).
  48. Simmons, C. A., Alsberg, E., Hsiong, S., Kim, W. J., Mooney, D. J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone. 35 (2), 562-569 (2004).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Bone RegenerationArtificial CartilageHyaluronic Acid HydrogelsCartilage DifferentiationIn Vivo Bone FormationChondrogenic DifferentiationScaffold MaterialsAngiogenesis Induction
Integrated Bone Formation Through In Vivo Endochondral Ossification Using Mesenchymal Stem Cells
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.